Search Results

You are looking at 31 - 40 of 1,186 items for :

  • "screening" x
  • Refine by Access: All x
Clear All
Full access

Colorectal Cancer Screening, Version 1.2015

Dawn Provenzale, Kory Jasperson, Dennis J. Ahnen, Harry Aslanian, Travis Bray, Jamie A. Cannon, Donald S. David, Dayna S. Early, Deborah Erwin, James M. Ford, Francis M. Giardiello, Samir Gupta, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, M. Sambasiva Rao, Scott E. Regenbogen, Moshe Shike, Gideon Steinbach, David Weinberg, Mary A. Dwyer, Deborah A. Freedman-Cass, and Susan Darlow

, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Colorectal Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colorectal Cancer

Full access

Implementation of NCCN Distress Management Guidelines by Member Institutions

Paul B. Jacobsen and Sean Ransom

The authors have no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1. Hoffman BM Zevon MA D'Arrigo MC . Screening for distress

Full access

NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018

Dawn Provenzale, Samir Gupta, Dennis J. Ahnen, Arnold J. Markowitz, Daniel C. Chung, Robert J. Mayer, Scott E. Regenbogen, Amie M. Blanco, Travis Bray, Gregory Cooper, Dayna S. Early, James M. Ford, Francis M. Giardiello, William Grady, Michael J. Hall, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Xavier Llor, Patrick M. Lynch, June Mikkelson, Reid M. Ness, Thomas P. Slavin Jr, Shajanpeter Sugandha, Jennifer M. Weiss, Mary A. Dwyer, and Ndiya Ogba

for Colorectal Cancer Screening Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colorectal Cancer Screening Disclosure of Relevant Financial Relationships The NCCN staff listed below

Full access

Implementing Routine Screening for Distress, the Sixth Vital Sign, for Patients With Head and Neck and Neurologic Cancers

Barry D. Bultz, Amy Waller, Jodi Cullum, Paula Jones, Johan Halland, Shannon L. Groff, Catriona Leckie, Lisa Shirt, Scott Blanchard, Harold Lau, Jacob Easaw, Konrad Fassbender, and Linda E. Carlson

/print certificate. Release date: October 25, 2013; Expiration date: October 25, 2014 Learning Objectives Upon completion of this activity, participants will be able to: Discuss the benefits that implementing a routine distress screening program had on

Full access

PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice

Timothy J. Wilt and Philipp Dahm

Few health issues have produced more controversy than prostate-specific antigen (PSA) screening for prostate cancer. Screening and early treatment for screen-detected disease may provide large personal and public health benefits. Prostate cancer

Full access

Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014

Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Wendy Demark-Wahnefried, Don Dizon, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Kristin Leonardi-Warren, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, Muhammad Raza, M. Alma Rodriguez, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Screening for

Full access

Financial Toxicity and Its Association With Prostate and Colon Cancer Screening

Michael J. Herriges Jr, Rachel Shenhav-Goldberg, Juliet I. Peck, Sumeet K. Bhanvadia, Alicia Morgans, Fumiko Chino, Thenappan Chandrasekar, Oleg Shapiro, Joseph M. Jacob, Alina Basnet, Gennady Bratslavsky, and Hanan Goldberg

children. Financial toxicity has been linked to delaying or forgoing cancer care after diagnosis. 12 – 14 However, little is known about the effect of financial toxicity on cancer prevention. Delaying recommended cancer screenings can potentially increase

Full access

Screening Performance for Frailty Among Older Patients With Cancer: A Cross-Sectional Observational Study of Two Approaches

Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto, and Tatsuo Akechi

Guidelines in Oncology (NCCN Guidelines) for Older Adult Oncology 13 recommend screening older patients with cancer for frailty using screening tools (to view the most recent version of these NCCN Guidelines, visit NCCN.org ). The Vulnerable Elders Survey

Full access

Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations

Sheena Bhalla, Vijaya Natchimuthu, Jessica L. Lee, Urooj Wahid, Hong Zhu, Noel O. Santini, Travis Browning, Heidi A. Hamann, David H. Johnson, Hsienchang Chiu, Simon J. Craddock Lee, and David E. Gerber

overall poor outcomes and prognosis. 2 Accordingly, prevention and early detection represent key considerations. Since 2013, the US Preventive Services Task Force (USPSTF) has endorsed annual low-dose CT (LDCT)–based lung cancer screening (LCS) in high

Full access

Update on PSA Testing

Mark L. Gonzalgo and H. Ballentine Carter

-confined prostate cancer is increased through prostate-specific antigen-based screening . JAMA 1993 ; 270 : 948 – 954 . 2. Catalona WJ Richie JP Ahmann FR . Comparison of digital rectal examination and serum prostate specific antigen in the early